ANDAINJECTIONINJECTABLE
Approved
Jan 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100
Mechanism of Action
[ See Microbiology ( ].
Indications (18)
the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniaeincluding cases associated with concurrent bacteremiaPseudomonas aeruginosaKlebsiella pneumoniaeEnterobacter speciesthe treatment of uncomplicatedcomplicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of Escherichia colithe infection is severecaused by Escherichia coliProteus mirabilisthe infection is mild to moderateincluding cases associated with concurrent bacteremia with these bacteriathe treatment of uncomplicated skinskin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only)Streptococcus pyogenesthe treatment of complicated intra-abdominal infections (used in combination with metronidazole) in adults caused by susceptible isolates of Escherichia coliviridans group streptococciBacteroides fragilis [ see Clinical Studies () ]